An interventional study of Patient Activation through Conversations (PACT) Program and Usual Care in Diabetes Mellitus and Diabetes Mellitus, Type 2, sponsored by National Healthcare Group Polyclinics. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by National Healthcare Group Polyclinics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore — 12 open to participants now, 20 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Singapore.
Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore, this one is the 24th largest by planned enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2024, is one of 50 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 100th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →12 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Novo Nordisk A/S · Sites in Singapore, Indonesia, Malaysia and 1 more country
Ages 40–70
Tan Tock Seng Hospital · Sites in Singapore
Ages 21–80
Boehringer Ingelheim · Sites in Singapore, United States, Argentina and 48 more countries
Ages 18+
Changi General Hospital · Sites in Singapore
Ages 21–70
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 21 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 6 · Phase 3 17 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 432 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 121 across the 98 interventional studies, 1,008 across the 14 observational. Of the 80 that completed or were terminated, 23 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 112 have an industry lead sponsor. The 10 most frequent:
National Healthcare Group Polyclinics is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
National Healthcare Group Polyclinics has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT06607497SingHealth PolyclinicsBetter Risk Perception Via Patient Similarity to Control Hyperglycemia and Sustained by Telemonitoring | 2026-12-31 |
| NCT06890169Changi General HospitalOneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities | 2027-02-28 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
| NCT07837934Tan Tock Seng HospitalColchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PACT Study is a cluster randomised trial of a health coach-led patient activation program in type 2 diabetes. The goal of this clinical trial is to evaluate the effectiveness of a health coaching intervention (PACT program) led by Care Coaches (trained lay persons), in adult participants with sub-optimally controlled Diabetes Mellitus, as compared to participants undergoing routine care for diabetes (Usual Care).
The primary outcome of interest is change in Glycated Haemoglobin (HbA1c) levels over 3 months, 6 months and 12 months. Secondary outcomes include changes in blood pressure, low-density lipoprotein-cholesterol (LDL-C) levels, body mass index (BMI), self-reported diabetes self-care behaviours, self-efficacy, health-related quality of life, and diabetes-related distress, over 3, 6 and 12 months.
Participants in the Intervention arm will undergo the PACT Program, which is a 3-month long health coaching program led by a care coach. Participants review their motivators, health parameters, self-care behaviours, and set goals for improving their diabetes using a PACT report. Subsequently, they will receive fortnightly motivational and problem solving support via telephone or WhatsApp messaging over a 3-month duration, and will return to routine care after 3 months. Participants in the Usual Care arm will have routine care of their diabetes treatment.
Study Methodology
This is a cluster randomised controlled trial comparing the PACT program to Usual Care. Each cluster consists of a Teamlet in a NHG Polyclinic, consisting of a regular group of Family Physicians, a Care Manager, and a Care Coordinator, that provide chronic care for a regular group of about 5000 patients.
Study Population
The study population will include patients with suboptimal control of diabetes (HbA1c >8%) between the ages of 21 to 64. Patients with a suboptimal control of diabetes frequently require a combination of both pharmacological and lifestyle measures for improvement of their glycaemic levels.
The inclusion criteria include the following:
The exclusion criteria includes the following:
These patients are excluded as they may have conditions that could be of a higher priority for management as compared to Diabetes Mellitus, and may not be able to provide informed consent or participate actively in shared decision making.
Summary of Study Design
The unit of randomisation will be each cluster, as represented by a single Teamlet. Randomisation will be carried out on all Teamlets that are involved in this research study from NHG Polyclinics. The study team aims to involve two to three polyclinics that includes six Teamlets in each polyclinic. A total of 12 to 18 Teamlets will hence be involved, subject to resource and recruitment considerations.
Teamlets in each polyclinic will be randomised to either the PACT Program condition or Usual Care condition. Patients who belong to Teamlets that are randomised to the PACT Program condition will be recruited for participation in the PACT Program, and patients who belong to Teamlets that are randomised to the Usual Care condition will be recruited and provided with routine care. Due to the nature of the PACT intervention, blinding of the Teamlet members (Doctor, Care Manager, Care Coach) and patients will not be feasible. The data analyst will be blinded to the group allocation.
The PACT Program intervention will last 3 months. Four participant assessments will be conducted, and this will take place at baseline and at the 3-month, 6-month, and the 12-month mark.
Recruitment of participants will take place over 12 months and follow-up of participants will be carried out over 24 months. Further analysis will be undertaken for 12 months, so the total length of the study will be 4 years and 0 months.
PACT program procedures The PACT program lasts 3 months and is a health coaching program for people with type 2 diabetes.
Patients have an in-person visit with a Care Coach at the baseline visit, where review of their metabolic parameters, self-care behaviors and health motivators is carried out, supported by use of a PACT form. This is followed by goal setting.
The PACT form consists of:
The Care Coach has been trained to apply a bio-psychosocial approach, motivational interviewing skills and provide diabetes care support. The discussion will take approximately 15 to 30 minutes.
Supportive follow-up is provided over the following 3 months. The Care Coach will support patients in reviewing their goals, assist in problem solving, and provide motivational support. Follow-up will be conducted 2 weekly via telephone calls and/or WhatsApp messages, according to the patient's preference. Care coaches will minimally send patients a whatsapp message or conduct a phone call, however, we acknowledge that some patients may not reply or pick up the phone. This will take approximately 10 to 20 minutes each time. After 3 months, the patients will be reverted back to routine clinical care.
Outcome Assessments
Patient outcomes will be assessed at baseline (12 months before study period), and at regular intervals over 24 months for clinical data. Patient reported outcomes will be assessed at 3, 6, and 12 months.
Clinical Outcomes
The outcomes that will be assessed include:
Patient reported outcomes
The baseline and follow-up questionnaires include the following measures:
Costs and resource utilisation will be analysed, including:
Sample Size and Statistical Methods
Estimation of Sample Size A minimal clinically important difference of 0.4% in HbA1c is expected between participants of the PACT program compared with Usual Care. In estimating the sample size, a standard deviation of 1.2% was used, as estimated from a local study. We aim to recruit between 12 to 18 Teamlets in the study. If 12 Teamlets are recruited (6 Teamlets are randomised to PACT and 6 to the control group), 34 subjects are required for each Teamlet (total 204 participants in the PACT program and 204 participants in Usual Care), at 80% power with one-sided alpha at 5%, and setting the intracluster correlation coefficient at 0.01 with an assumed drop-out rate of 20%. If 18 Teamlets are recruited (9 randomised to PACT and 9 to the control group), 24 subjects are required for each Teamlet (216 participants in the PACT program and 216 participants in Usual Care), at 80% power with one-sided alpha at 5%, and setting the intracluster correlation coefficient at 0.01 with an assumed drop-out rate of 20%. Sample size calculations were conducted using SampSizeV2.
Statistical and Analytical Plans
Effectiveness outcomes may include differences between PACT and controls in terms of HbA1c, DM-related complications, DM-related deaths, or quality-adjusted life years (QALYs).
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's planned enrollment of 432 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →National Healthcare Group Polyclinics is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention arm will undergo the PACT Program, which is a 3-month long health coaching program.
Behavioral: Patient Activation through Conversations (PACT) Program
Patients in the Usual Care Arm will undergo routine follow-up for their Diabetes Mellitus. In NHGP, this involves Teamlet care, where patients are taken care of by a team comprising of Family Physicians, a Care Manager (a nurse trained in chronic disease management), and a Care Coordinator, and are seen typically every three to six months for monitoring of their diabetic control.
Behavioral: Usual Care
Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
Routine Chronic Disease care
HbA1c
Glycated Hemoglobin
Time frame: 24 Months
Blood Pressure
Systolic and Diastolic Blood Pressure
Time frame: 24 months
BMI
Body Mass Index
Time frame: 24 months
LDL-C
Low density Lipoprotein cholesterol
Time frame: 24 months
eGFR
Estimated glomerular filtration rate
Time frame: 24 months
uACR
Urine Albumin:Creatinine Ratio
Time frame: 24 months
uPCR
Urine Protein:Creatinine Ratio
Time frame: 24 months
Summary of Diabetes Self-Care Activities Scale (SDSCA)
SDSCA is a measure of self-care behaviors in diabetes. It is divided into the following five domains: Diet , Physical Activity, Blood Sugar Testing, Medication Adherence, and Smoking. There are 11 items, with each scored from 0 -7. Higher scores indicate a better outcome. Smoking status is scored using Yes/No.
Time frame: 12 months
2-item Diabetes Distress Scale (DDS-2)
The 2-item Diabetes Distress Scale (DDS-2) measures Diabetes Related Distress. It includes two items, each scored from 1 - 6. Higher scores indicate a worse outcome
Time frame: 12 months
Diabetes Empowerment Scale (DES-SF)
Diabetes Empowerment Scale (DES-SF) is a measure of diabetes empowerment, consisting of 8 items, each scored from 1 - 5. Higher scores indicate a better outcome.
Time frame: 12 months
EuroQol group 5-Dimension 5-Level Scale (EQ-5D-5L)
The EQ-5D-5L is a measure of Health-related quality of life. It is divided into the following five domains: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression (each question scored from 1-5, Higher scores indicate a worse outcome), as well as a Visual Analog Scale (scored from 0- 100, Higher scores indicate a better outcome.)
Time frame: 12 months
5 questions from the Patient Satisfaction Questionnaire-III
5 questions from the Patient Satisfaction Questionnaire-III are used as a measure of patient satisfaction in the PACT Arm. It includes five items, each scored between 1-5. Higher scores indicate a worse outcome.
Time frame: 3 months
CollaboRATE scale.
The collaboRATE scale is a measure of shared-decision making. It includes three items, each scored between 0-9. Higher scores indicate a better outcome.
Time frame: 3 months
Referral to community exercise programs
Patient-reported information for referral to community exercise programs
Time frame: 12 months
Adverse events
Patient-reported hypoglycaemic episodes requiring emergency department visit and/or admissions to hospital
Time frame: 12 months
Drugs Prescribed
Drug prescribed, dosage, and cost
Time frame: 24 months
Costs and resource utilisation
Health-service utilisation costs, training costs, laboratory tests costs, medication costs
Time frame: 24 months
Plan to share: No
Started Apr 2024 (actual). Primary completion is estimated for Mar 2025, 11 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 11 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Healthcare Group Polyclinics